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Summary
Accurate diagnosis of rare inherited anaemias is challenging, requiring a
series of complex and expensive laboratory tests. Targeted next-generation-
sequencing (NGS) has been used to investigate these disorders, but the
selection of genes on individual panels has been narrow and the validation
strategies used have fallen short of the standards required for clinical use.
Clinical-grade validation of negative results requires the test to distinguish
between lack of adequate sequencing reads at the locations of known
mutations and a real absence of mutations. To achieve a clinically-reliable
diagnostic test and minimize false-negative results we developed an
open-source tool (CoverMi) to accurately determine base-coverage and the
‘discoverability’ of known mutations for every sample. We validated our
33-gene panel using Sanger sequencing and microarray. Our panel demon-
strated 100% specificity and 997% sensitivity. We then analysed 57 clinical
samples: molecular diagnoses were made in 22/57 (386%), corresponding
to 32 mutations of which 16 were new. In all cases, accurate molecular
diagnosis had a positive impact on clinical management. Using a validated
NGS-based platform for routine molecular diagnosis of previously undiag-
nosed congenital anaemias is feasible in a clinical diagnostic setting,
improves precise diagnosis and enhances management and counselling of
the patient and their family.
Keywords: inherited anaemia, congenital dyserythropoietic anaemia,
molecular genetics, pyruvate kinase deficiency, next-generation sequencing.
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Diagnosis of the cause of anaemia is usually straightforward
using simple laboratory tests (e.g. assessment of iron status,
haemoglobin high performance liquid chromatography). In
contrast, for patients with uncommon or rare congenital anae-
mias, many of which are severe, reaching a precise diagnosis is
often extremely difficult and may take several years (Magor
et al, 2005; Paessler & Hartung, 2015; Van Zwieten et al,
2015). With the exception of red cell membrane disorders, red
cell morphology is often non-specific (Koralkova et al, 2014)
and may require exceptional expertise; many investigations are
expensive and restricted to specialist laboratories (Grace et al,
2015). Thus, it is unsurprising that many patients with rare
congenital anaemias have no precise diagnosis, which prevents
effective patient management and genetic counselling.
Eventually, whole-genome sequencing (WGS) may become a
realistic diagnostic tool to be used early in the investigation of
inherited conditions and has recently shown promising results
in a study of critically ill neonates with suspected genetic diag-
noses 57% (Petrikin et al, 2015). However, despite increasing
accessibility and cost effectiveness of sequencing technology
and analysis (Meienberg et al, 2016), interpretation of the data
remains complex and the overall utility of WGS in a clinical
context is still being investigated. Meanwhile, targeted next-
generation-sequencing (NGS) is a popular approach for pro-
viding rapid and accurate mutation analysis as the use of a lim-
ited panel of genes facilitates the interpretation and reduces
incidental findings (Sun et al, 2015). While targeted NGS has
been reported for the investigation of various anaemias and/or
pancytopenia (Gerrard et al, 2013; Collopy et al, 2014; De
Rocco et al, 2014; Christensen et al, 2015; Ghemlas et al, 2015;
Zhang et al, 2015), these studies have reported only research-
grade validation strategies, usually by ensuring that a small
number of variants or single nucleotide polymorphisms (SNPs;
ranging from 2 to 53 variants) identified by Sanger sequencing
could also be detected by NGS. While these panels are valuable
in the research context for the positive identification of novel
mutations in known genes, they cannot be reliably used in a
clinical context because ‘negative’ results do not distinguish
between the absence of mutations on the one hand and lack of
adequate sequencing reads at the locations of known mutations
on the other. This is now essential for medical laboratory
accreditation in some countries, including the UK.
Here, we report the development and application of a
novel clinical-grade open-source tool for evaluation of ‘per-
base coverage’ in a 33 gene-targeted NGS panel (Oxford Red
Cell Panel, ORCP) used to provide a clinical diagnosis to
patients with unexplained anaemia. Specifically, we aimed to
(i) demonstrate the feasibility of achieving clinical-grade vali-
dation of a targeted re-sequencing panel for congenital anae-
mias; (ii) develop a clinical-grade open-source tool for
evaluation of read coverage; (iii) assess the diagnostic yield
of this strategy for congenital anaemias and (iv) assess the
clinical impact of results generated using this approach. To
select the genes for inclusion in the ORCP we chose to take
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a relatively unbiased approach by including causative genes
for conditions where anaemia may be part of a wider bone
marrow failure syndrome as well as those for specific red cell
disorders, such as Diamond–Blackfan Anaemia (DBA) and
Congenital Dyserythropoietic Anaemia (CDA).
Materials and methods
The workflow from sample preparation to clinical interpreta-
tion is shown in Fig S1. In most cases, targeted NGS was only
performed after standard investigations, such as erythrocyte
adenine deaminase (eADA) levels and chromosomal breakage
studies, had been performed. All additional tests performed
are included in Table SI. Patients with microcytic hypochro-
mic indices were tested for haemoglobinopathies by direct
sequencing of the HBA1/2 and HBB genes and multiplex gap-
polymerase chain reaction (PCR) to exclude the common 37
and 42 kb single HBA1/2 gene deletions. Multiplex ligation-
dependent probe amplification (MLPA) was undertaken where
appropriate to investigate the presence of other deletions or
duplications of HBA1/2 or HBB.
The study was approved by the Wales Research Ethics
Committee (REC5) (13/WA/0371) with written consent from
patients and/or parents.
Design of the ORCP (Oxford Red Cell Panel)
Genes were selected from the literature and the Human Gene
Mutation Database (HGMD; http://www.biobase-internatio-
nal.com/product/hgmd) as causative for the anaemias under
study (Table I, Table SII). ILLUMINA DESIGNSTUDIO v1.0 was used
to design the TruSeq Custom Amplicon panel (TSCA) (both
Illumina, San Diego, USA) to 249 specified regions using
425 bp amplicons with UCSC hg19 (https://genome.ucsc.edu/
cgi-bin/hgTracks?db=hg19&lastVirtModeType=default&last-
VirtModeExtraState=&virtModeType=default&virtMode=0&-
nonVirtPosition=&position=chr21%3A33031597-33041570&
hgsid=498013795_KW6GKVQmp3e84XkCP3AAdx93cKft) as
the reference genome. A total of 498 amplicons were designed
to capture exons and intron/exon boundaries. Promoter
regions were included in the design.
Library preparation and sequencing
Library preparation was performed with ILLUMINA’S TSCA v1.5
kit (FC-130-1001) using 250 ng genomic DNA, following
manufacturer’s instructions. Samples were pooled (average 26
samples) and loaded at 20 pM on MiSeq using a v3 600-cycle
reagent kit sequencing 2x301 paired-end reads (Illumina).
Sanger sequencing
Sequencing was performed on an ABI3730 DNA Analyser
(Applied Biosystems, Foster City, CA, USA) using 200–
500 ng DNA template, BigDye (Applied Biosystems) reaction
mix, and 32pmol sequencing primer. Chromatograms were
visualized with SEQUENCHER v4.8. (Gene Codes Corp, Ann
Arbor MI, USA).
MPLA and SNP array
Given that ~20% of cases of DBA (Farrar et al, 2011) are
caused by ribosomal protein gene deletions, a commercial
MLPA kit was used to detect deletions in the following
genes: RPL11, RPL35A, RPS17, RPS19, RPS26, and RPL5
(MRC Holland, Amsterdam, the Netherlands). Infinium
Human OmniExpress Exome v1.2 beadchips (Illumina) were
run using 200 ng DNA following the manufacturer’s protocol
for Infinuim HD assay super manual workflow and immedi-
ately scanned using Illumina iScan. Data were analysed using
ILLUMINA GENOMESTUDIO (v2011.1).
Bioinformatics and mutation calling
Sequencing reads were aligned and variants called against refer-
ence genome (hg19) using the MISEQ REPORTER SOFTWARE
(v2.2.290, Illumina) and the TSCA panel manifest. Variants
were annotated and filtered using VARIANTSTUDIO (v2.2, Illu-
mina). Variant filters were established using a sample set with
known mutations and filter settings verified using blinded sam-
ples: quality score >100; passing filter; total read frequency of
>30, mutant allele frequency of ≥20%; variant present in <5%
of the population; of consequence– missense, frameshift, stop
gained, stop lost, initiator codon, in-frame insertion, in-frame
deletion, splice. Filtered variants were visualized in genomic
context using IGV (Interactive Genomics Viewer: http://
www.broadinstitute.org/igv/) to exclude sequencing artifacts.
CoverMi
To report coverage/base and discoverability of all known
variants we developed an open-source tool, CoverMi, written
Table I. Genes included on the Oxford red cell panel.
Condition Genes
Congenital
Dyserythropoietic
Anaemia (CDA)
C15ORF41, CDAN1, SEC23B, KIF23, KLF1
Diamond–Blackfan
Anaemia (DBA)
RPL11, RPL26, RPL35A, RPL5, RPS10,
RPS17, RPS19, RPS24, RPS7, RPL19, RPL27,
RPL9, RPS26, RPS29, RPS27, GATA1
Schwachman-
Diamond
Syndrome (SDS)
SBDS
Dyskeratosis
Congenita (DKC)
DKC1, NHP2, NOP10, TERT, TERC, TINF2
Sideroblastic
Anaemia
ALAS2, SLC25A38
Red cell enzyme
deficiencies
G6PD, PKLR, NT5C3A
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in Python (v2.7.6) and R (v3.1.2) and run on Windows,
Linux and OSX. It utilizes Bedtools (v2.221, http://bed-
tools.readthedocs.org) to extract raw coverage information
from the alignment.bam file and maps this to the gene, exon
and variant locations on the UCSC hg19 reference genome.
CoverMi has a simple graphical user interface designed for
use by laboratory scientists and clinicians without extensive
bioinformatics knowledge. CoverMi can be used with any
sequencing data generated by Illumina or ThermoFisher
platforms; it is licensed under an MIT open-source license
and is freely available for download at https://github.com/
eawilson/covermi.
The American College of Medical Genetics (ACMG)
guidelines were used for reporting of genetic variants (Rehm
et al, 2013): Tier 1- variants reported in the literature, cata-
logued in HGMD and validated as pathogenic. Tier 2-
variants expected to cause the disorder due to a predicted
shift in mRNA reading frame, mutation of the initiation or
stop codon, introduction of a novel stop codon or alteration
of the highly-conserved GT/AG nucleotides at a splice junc-
tion, but not previously described or described only in a
related phenotype; and Tier 3- variants that may or may not
be causative of the disorder. These include pathogenic muta-
tions in genes not normally thought to cause this particular
phenotype or those predicted to produce a cryptic splice
site, to affect transcription, or non-conservative missense
mutations with a high deleterious predictive score (e.g. by
algorithms such as SIFT or Polyphen2). Where it was diffi-
cult to determine pathogenicity, parental or other familial
DNA was sought so that the variants could be traced to
determine whether they segregate with the disease. Where
two known pathogenic variants were co-inherited, each
being causative for a different autosomal recessively inher-
ited anaemia, we did not conclude that they are pathogenic
when inherited together without carrying out further func-
tional analysis and they remain ‘unsolved’. Our laboratory
follows the latest ACGM guidelines (Richards et al, 2015)
and undertakes regular reviews to see whether any previ-
ously identified variants of uncertain significance (VUSs)
have now been reported as either pathogenic or non-patho-
genic. The ORCP has undergone certification according to
International Organization for Standardization (ISO)
standard 015189 of the United Kingdom Accreditation Ser-
vice (UKAS), the medical laboratory accreditation authority
in the UK and can accept diagnostic referrals from within as
well as outside the UK.
Results
Validation of ORCP
Validation of ORCP followed the 2013 ACMG guidelines
(Rehm et al, 2013). Sensitivity and specificity: 44 unique vari-
ants identified by ORCP were confirmed by Sanger sequenc-
ing (one sequence variant previously identified by Sanger
sequencing was not detected by ORCP using set filters).
Using the array comparative genomic hybridization microar-
ray platform, comparison of the 283/273,000 features over-
lapping with ORCP amplicons (16 variants; 267 reference
calls) showed 100% concordance, indicating 100% specificity
and 997% sensitivity (95% confidence interval 979–999%).
Of the 1207 variants in the 33-gene panel described in
HGMD, 87% are missense changes, 4% simple insertions,
8% deletions and 1% complex insertions/deletions (indels).
Of the 44 variants tested, 11% were insertions and 8% dele-
tions, satisfying ACMG guidelines that positive controls
include variants representative of naturally-occurring disease-
causing traits. Robustness and assay precision: To test within-
run and between-run variability, we took a much more strin-
gent approach than used in research-grade targeted NGS
panels (Gerrard et al, 2013; Collopy et al, 2014; De Rocco
et al, 2014; Christensen et al, 2015; Ghemlas et al, 2015;
Zhang et al, 2015) by assaying 13 samples in duplicate and 4
in triplicate (66 variants in total, 100% of which were found
on repeat sequencing).
An open-source tool (CoverMi) reports coverage-per-base
and ‘discoverability’ of known variants
Available commercial analysis software may incorrectly label
variants as ‘discoverable’ as they report mean coverage per
whole amplicon, potentially masking areas of low coverage
flanking central overlapping regions between forward and
reverse reads (Fig S2). We therefore developed CoverMi to
Figure 1. Discoverability of individual mutations across different genes on the Oxford Red Cell Panel using CoverMi software (A) Top panel:
Box and whisker plot showing the percentage of known variants that are discoverable (coverage depth >30) for 72 samples over 5 separate MiSeq
runs. Bottom panel shows the total number of variants for each corresponding gene as reported in the Human Gene Mutation Database
(HGMD). Genes not depicted on this figure do not have any variants reported in HGMD. (B) Graphical representation of coverage over the
GATA1 gene for a single sample. The six exons that comprise the GATA1 gene are displayed along the bottom of the graph and the overlapping
black bars represent the ten amplicons that cover this gene. The minimum read depth for reliable detection is represented by the dotted line,
along which crosses mark the locations of the known variants in each exon. It can be seen that there is adequate coverage over eight of the ten
amplicons, however the second and seventh amplicons have failed. The seventh amplicons covers an intergenic region with no known variants,
but the second amplicon covers exon 2, which contains two known variants. Loss of coverage over this region will increase the false negative rate
of the assay in this particular sample. (C) Individual mutation coverage summary per gene per sample. For each sample on each run, CoverMi
determines the percentage of known mutations in each of the genes tested that would be discoverable in that sample, by calculating the number
of reads at individual nucleotide positions corresponding to previously described mutations. Where this ratio is <90%, the gene is highlighted in
grey to indicate that overall coverage falls below accepted standards.
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accurately calculate the sensitivity of ORCP for each sample
by measuring precise read depth at each variant location. The
performance of ORCP for 1207 known variants in 33 genes
was tested on 72 samples over 5 MiSeq runs (minimum cover-
age depth 30x). ~90% of variants were detectable for each
sample (range 84–92%); most genes had consistent coverage
(e.g. SEC23B, RPL11) but a small number (e.g. PKLR, TERC)
showed variability between samples (Fig 1A). The importance
of coverage assessment is illustrated in Fig 1B, which shows
good coverage of exons 4 and 6 which contain known variants,
but failure of the exon 2 amplicon means the presence or
absence of known mutations in this exon cannot be deter-
mined for this sample. Reports of variant coverage are gener-
ated for each sample per run (Fig 1C) and used to guide
decisions to repeat NGS or use alternative strategies, such as
Sanger sequencing, e.g. where key variants that account for a
high proportion of cases are not discoverable.
Diagnostic yield and clinical impact of ORCP for
congenital anaemia
Following our extensive clinical-grade validation and the
development of our CoverMi tool, 57 clinical samples were
analysed using ORCP (Fig 2A, Table II, Tables SI and SIII).
The ‘working diagnosis’ submitted by treating physicians was
used but further details requested where molecular results
were inconsistent with this. In 22/57 cases a molecular diag-
nosis was made using ORCP giving a diagnostic yield of
386%. Of these 22 cases, 17 confirmed the clinical diagnosis,
two were new diagnoses in ‘unexplained anaemia’ patients
and three caused a change of diagnosis, substantially altering
treatment for these five patients (Fig 2B). For the remaining
35 cases, no molecular diagnosis was made, including two
patients harbouring TERT mutations of uncertain signifi-
cance and one patient with two SEC23B mutations of
Diagnostic yield
Clinical impact
Congenital anaemia
n = 57
Physician diagnosis prior to molecular analysis on ORCP
Congenital
Dyserythrop.
Anaemia
n = 20
Diagnosis aer molecular analysis on the ORCP
Enzyme
Deficiency
n = 4
Sidero-
blasc
Anaemia
n = 3
Diamond
Blackfan
Anaemia
n = 11
Unexplained
Anaemia
n = 19
Yes
n = 11 (55%)
Yes
n = 1 (25%)
Yes
n = 1 (33%)
Yes
n = 7 (64%)
Yes
n = 2 (11%)
Congenital
Dyserythrop.
Anaemia
n = 9
Pyruvate
Kinase
Deficiency
n = 1
Pyruvate
Kinase
Deficiency
n = 1
Pyruvate
Kinase
Deficiency
n = 1
Pyrimidine 5’
Nucleodase
Deficiency
n = 1
Sidero-
blasc
Anaemia
n = 1
Diamond
Blackfan
Anaemia
n = 6
Diamond
Blackfan
Anaemia
n = 1
Schwachman
Diamond
Syndrome
n = 1
Diagnosis confirmed; genetic counselling and treatment options defined
Diagnosis changed; major change to treatment, genetic counselling
New diagnosis; genetic counselling and treatment options defined
No mutations identified; patients offered WGS
(A)
(B)
Fig 2. Diagnostic yield and clinical impact of
targeted NGS for congenital anaemia. (A)
Breakdown of the cases by working diagnosis,
showing the proportion of cases where the
diagnosis was confirmed or established by tar-
geted next generation sequencing (NGS) using
the Oxford Red Cell Panel (ORCP). (B) Clini-
cal impact of targeted NGS for diagnosis of
congenital anaemia. CDA, Congenital Dysery-
thropoietic Anaemia; DBA, Diamond–Blackfan
Anaemia; SDS, Schwachman-Diamond Syn-
drome; WGS, whole genome sequencing.
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uncertain significance (Table SIV). Further investigations of
these cases are continuing, including offering WGS to the
families.
Diamond–Blackfan anaemia. Of 11 cases diagnosed by refer-
ring physicians as DBA, six harboured heterozygous mutations
in ribosomal protein (RP) genes predicted to be pathogenic
matching their bone marrow findings. In 3/6 cases, the
absence of mutations in parental samples indicated the muta-
tions were de novo. An additional patient, a 16-month-old boy
with a history of low birthweight and failure to thrive, initially
presented with anaemia and a bone marrow aspirate showed
markedly reduced erythropoiesis together with normal myelo-
poiesis. At this point his neutrophil count was normal leading
to a diagnosis of DBA. Following molecular analysis using the
ORCP he was found to have a homozygous known pathogenic
mutation in the SBDS gene (c.258 + 2T) and mild neutrope-
nia developed at around that time. Sanger sequencing con-
firmed both parents were carriers and a revised diagnosis of
Shwachman–Diamond Syndrome was confirmed by low faecal
elastase (<15 lg/g; normal >200 lg/g). For the remaining 4/
11 cases diagnosed clinically as DBA, no pathogenic mutations
were identified and MLPA excluded deletions in RPL11,
RPL35A, RPS17, RPS19, RPS26 and RPL5. Interestingly, the
panel identified one additional patient with a previously
reported RPS19 mutation (Willig et al, 1999). This patient
(Patient 44 [P44]), who had been submitted for investigation
with a clinical diagnosis of CDA, presented at age 4 months
with severe transfusion-dependent anaemia, mild reticulocyto-
sis (56%) and a normocellular marrow with relative erythroid
hyperplasia. Two subsequent bone marrow aspirates at 7 and
12 months of age showed significant dyserythropoiesis,
prompting Electron Microscopy (EM) examination which was
reported as suspicious of CDA-I, with ~50% of erythroblasts
exhibiting ‘Swiss cheese heterochromatin’ (Fig 2, Table II).
Congenital dyserythropoietic anaemia. Nineteen cases were
referred with probable CDA-I and one with unclassified CDA
(P38). Mutations in CDAN1 were identified in 8/19 CDA-I,
including four cases of homozygosity for known (P39 and
P40) or predicted (P51 and P53) pathogenic mutations, three
cases of compound heterozygosity for one known and one
predicted pathogenic mutation (P49, P50 and P55) and one
compound heterozygosity for two known mutations (P56).
The diagnosis of CDA-I was confirmed by EM in all five
patients with novel mutations in CDAN1. In P50 the 7 bp
insertion results in a frameshift and premature stop codon
(c.2971_2977dupGCAGCAG) predicted to result in tran-
scripts susceptible to nonsense-mediated decay. Sequencing
of genomic DNA and complementary DNA (cDNA) con-
firmed the insertion was absent from cDNA rendering the
patient functionally homozygous for the 2015C>T exon 14
mutation and therefore clinically affected (Fig S3). P38,
referred with unclassified CDA, had compound heterozygos-
ity for two pathogenic KLF1 mutations previously reportedT
ab
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in CDA-IV, although not previously documented in the same
patient (Gallienne et al, 2012; Viprakasit et al, 2014). The
clinical features, early-onset transfusion-dependent, micro-
cytic anaemia with reticulocytosis, jaundice, hep-
atosplenomegaly, high HbF (142%) and bone marrow
erythroid hyperplasia with binucleate erythroblasts and
chromatin bridges, were also consistent with CDA-IV. Two
further cases clinically diagnosed as CDA-I (P44 and P54)
were found to have mutations in non-CDA genes (RPS19 as
discussed above) and PKLR. The latter (P54) was an 18-
month-old transfusion-dependent girl in whom bone marrow
analysis showed erythroid hyperplasia with significant dysery-
thropoiesis and ~30% of erythroblasts were reported as
exhibiting ‘Swiss-cheese heterochromatin’, leading to a clini-
cal diagnosis of CDA and pyruvate kinase (PK) levels were
therefore not tested. After molecular analysis revealed com-
pound heterozygosity for PKLR mutations, PK levels were
tested and found to be low and central review of the marrow
morphology was felt to be consistent with non-specific
dyserythropoiesis rather than CDA. The patient subsequently
became transfusion independent after splenectomy (Fig 2,
Table II).
Sideroblastic anaemia. Of three cases diagnosed by referring
physicians as sideroblastic anaemia, one (P33) was homozygous
for a mutation in SLC25A38 predicted to be pathogenic due to
a frameshift leading to an early termination codon consistent
with the bone marrow findings. For the remaining two cases no
pathogenic mutations were identified (Fig 2, Table II).
Enzyme deficiencies. Pathogenic mutations were identified in
1/4 cases with haemolytic anaemia suspected to be due to red
cell enzyme deficiency. NP37 was a compound heterozygote
for known pathogenic PKLR mutations and the diagnosis was
confirmed with low PK levels. For the remaining three cases,
no pathogenic mutations were identified (Fig 2, Table II).
Unexplained anaemia. Of the 19 patients where referring
clinicians were unable to make any diagnosis using conven-
tional investigations, ORCP produced a definitive molecular
diagnosis in 2/19: PK deficiency (P9), and pyrimidine 5
nucleotidase (P5’N) deficiency (P14). P9, who has compound
heterozygosity for two known pathogenic mutations in the
PKLR gene, presented with neonatal liver failure and idio-
pathic inflammatory giant cell hepatitis and developed
microcytic transfusion-dependent anaemia with splenomegaly
and reticulocytosis by 6 months of age. His blood film
showed no basophilic stippling or echinocytes; PK assays
were normal; and bone marrow examination showed only
moderate erythroid hyperplasia; parental blood counts and
films were normal. However, prompted by the targeted NGS
results, repeat PK assays revealed reduced levels in the
patient and both parents. P14 is a compound heterozygote
for one known and one predicted pathogenic mutation in
NT5C3A, the gene causing P5’N deficiency, confirmed by
reduced enzyme levels. Interestingly, the blood film showed
almost no basophilic stippling, explaining why this diagnosis
was not suspected clinically. For the remaining 17/19 cases of
unexplained anaemia, no pathogenic mutations in ORCP
genes were identified although one case (P13) was found to
have mutations of uncertain significance in SEC23B, which
may be partly responsible for her anaemia (Table SIV)
(Fig 2, Table II).
Discussion
We set out to develop a clinical-grade, targeted NGS panel
to facilitate precise diagnosis of unexplained congenital anae-
mias, many of which had undergone repeated, unsuccessful
investigations over many years. The use of targeted NGS in
inherited anaemias/pancytopenia has been investigated by
several groups in conditions such as DBA, bone marrow fail-
ure, Fanconi Anaemia and neonatal haemolytic anaemia
(Gerrard et al, 2013; Collopy et al, 2014; De Rocco et al,
2014; Christensen et al, 2015; Ghemlas et al, 2015; Zhang
et al, 2015). In contrast to these studies, our study employed
novel analytical and validation strategies to ensure that the
ORCP was suitable for reliable diagnosis in a clinical setting
and is accredited by UKAS, the medical laboratory accredita-
tion authority in the UK. Furthermore, we chose to take a
relatively unbiased approach by including causative genes for
conditions where anaemia may be part of a wider bone mar-
row failure syndrome as well as those for specific red cell dis-
orders, such as DBA or CDA. Thus, our study contrasts with
previously reported studies of targeted NGS, which have
focused on well-phenotyped cases, mostly with an established
clinical diagnosis and a narrower range of genes. While this
more targeted approach is likely to miss ‘atypical’ cases, we
acknowledge that our broader approach probably led to a
lower diagnostic yield in cases with classical features of unex-
plained anaemia without other associated cytopenias.
While the approach of choosing a narrow set of genes can
speed up diagnosis and allow appropriate genetic counselling,
it can, at best, confirm the clinically-suspected diagnosis, as
shown in previously published studies which reported >80%
diagnostic yields (Gerrard et al, 2013; Collopy et al, 2014; De
Rocco et al, 2014; Christensen et al, 2015; Ghemlas et al,
2015; Zhang et al, 2015). Similarly, for most of our cases,
confirmation of a suspected diagnosis by molecular analysis
also allowed provision of accurate information for genetic
counselling for the first time in 17/57 (~30%) of cases. Par-
ticularly crucial were the seven patients in whom we estab-
lished the molecular basis of DBA and accurate genetic
counselling was provided by identifying de novo cases, where
the recurrence risk is extremely low, from familial cases. Fur-
thermore, appropriate treatment, surveillance and prophy-
laxis were also instituted for the first time for P14 (P5’N
deficiency), P23 (SDS) and P44 (DBA).
Use of the ORCP to make an accurate molecular diagnosis
had life-changing impacts for several of the patients and their
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families, particularly for patients P9 and P54 for whom a
new diagnosis of PK deficiency led to transfusion-indepen-
dence and cessation of iron chelation following splenectomy.
PK deficiency had previously been missed due to repeatedly
normal PK enzyme levels, a well-recognized pitfall especially
in transfusion-dependent patients (Koralkova et al, 2014).
For P44, initially misdiagnosed as CDA-I, the correct diagno-
sis of DBA dramatically changed the prognosis, response to
therapy and genetic counselling offered to the family. This
case was atypical for DBA, as there was initial reticulocytosis
and erythroid hyperplasia on three separate marrow
aspirations, so DBA was not considered in the differential
diagnosis.
Targeted NGS offers several advantages over the tradi-
tional specialized investigations used to diagnose congenital
anaemia. Firstly, the risk of a wrong diagnosis is reduced
given the practical and technical limitations of biochemical
assays and EM interpretation without molecular confirma-
tion. Indeed, our study shows that mis-diagnosis of CDA-I
is fairly common, as the degree of bone marrow dysery-
thropoiesis in haemolytic conditions, although noted in
previous case reports (Haija et al, 2014), remains under-
appreciated. Cases of CDA-I submitted for molecular analy-
sis were not felt to show CDA-I- specific features when
reviewed by our specialist pathologist, highlighting the diffi-
culty of relying on morphological findings alone to make a
diagnosis of CDA. A second advantage of targeted NGS is
that, unlike most tests for unexplained congenital anaemia,
it can be reliably performed in regularly-transfused patients
and samples can be sent by post without specialized pro-
cessing or shipping.
The validation strategy we have used fulfilled the require-
ments set out by the ACMG for NGS panels to be used in
the diagnostic setting, in contrast to previous studies (Ger-
rard et al, 2013; Collopy et al, 2014; De Rocco et al, 2014;
Christensen et al, 2015; Ghemlas et al, 2015; Zhang et al,
2015). Crucially, assessment of coverage in these studies
relied on assessment of overall coverage and did not account
for the coverage at the specific locations where mutations
have previously been described in all of the genes tested. We
therefore developed a novel bioinformatic algorithm, Cov-
erMi, to assess the per-base read coverage of all locations
where mutations have previously been described. This
approach, which has not previously been reported, allows
haematologists to make the distinction between the absence
of mutations and the lack of adequate sequencing reads at
the locations of known mutations. We propose that such an
approach should be essential for a NGS panel to be used for
clinical diagnosis and here we make it freely available to
other users.
Typically, diagnosis of unexplained congenital anaemia
involves sequential investigations including routine haemato-
logical and biochemical tests followed by specialized tests
(e.g. red cell enzyme assays, bone marrow morphology) and,
finally, testing of individual genes directed by these
investigations. Our targeted panel may allow the diagnostic
pathway to be shortened by performing NGS before special-
ized investigations. For many patients this would dramati-
cally reduce the time to diagnosis and the number of
expensive, complex tests, as specific confirmatory tests can be
targeted to individual patients to confirm the molecular diag-
nosis. Indeed, the average time to diagnosis for the five new/
changed diagnoses in our study was 33 years, rather than
3 months had NGS been available earlier. However, we
acknowledge that several strategies will be needed to increase
the diagnostic yield of targeted NGS for congenital anaemia
before this approach will replace conventional diagnostic
approaches. In particular, we plan to include a larger number
of red cell enzyme genes and add red cell membrane genes to
the panel. Furthermore, the diagnostic utility of such panels
depends on a regular process of review to accommodate rele-
vant newly identified pathogenic and modifying mutations in
genes and their promoters and regulatory elements (Crispino
& Weiss, 2014). It is likely that whole exome sequencing or
whole genome sequencing, which provide a much more
comprehensive, unbiased approach, will replace targeted
sequencing in the future. At present, however, the use of a
restricted, targeted panel requires less complex analysis with
fewer incidental findings (Sun et al, 2015) and is a practical
approach to achieving a rapid, accurate diagnosis where rou-
tine investigations have failed.
In conclusion, we demonstrate the feasibility of using a
clinical-grade NGS panel in routine clinical diagnosis of rare
congenital anaemias. This approach has a good diagnostic
yield (386%), which leads to improved, tailored patient
management. Our NGS data validation shows 100% speci-
ficity and reproducibility with high sensitivity. Finally, evi-
dence from other inherited diseases indicates that accurate
and timely diagnosis improves patient well-being by reducing
the anxiety associated with inaccurate prognostic information
(Lenhard et al, 2005).
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